ASH 2022 | The role of the cardio-oncologist in the treatment of patients with hematological malignancies

Chan Yoon Cheah • 9 Dec 2022

ASH 2022

General BTK inhibitors

Chan Yoon Cheah, MBBS, Linear Clinical Research and Sir Charles Gairdner Hospital, Perth, Australia, explains the critically important role of the cardio-oncology team in the treatment of patients with hematological malignancies. Dr Cheah comments specifically on the challenges of managing the development of atrial fibrillation on top of pre-existing cardiac comorbidities, and also highlights the importance of being able to identify patients at risk of developing severe cardiotoxicities when treated with Bruton’s tyrosine kinase inhibitors (BTKis). This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Beigene: Consultancy, Honoraria; TG Therapeutics: Consultancy, Honoraria; Eli Lilly and Company: Consultancy, Honoraria; AstraZeneca: Consultancy, Honoraria; Novartis: Consultancy, Honoraria; Bristol Myers Squibb: Consultancy, Honoraria, Research Funding; Gilead: Consultancy, Honoraria; Merck Sharp & Dohme: Consultancy, Honoraria; Janssen: Consultancy, Honoraria; Roche: Consultancy, Honoraria, Research Funding.